Recurrence of glomerulonephritis after renal transplantation

Transplantation Reviews

Volumn 27, Issue 4, 2013, Pages 126-134

  Sprangers, Ben ^a   Kuypers, Dirk R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; BORTEZOMIB; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; EPRODISATE; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEGINTERFERON; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AMYLOIDOSIS; ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DRUG MEGADOSE; FOCAL GLOMERULOSCLEROSIS; GENETIC ANALYSIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GRAFT FAILURE; GRAFT SURVIVAL; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; PARAPROTEINEMIA; PATHOGENESIS; PLASMA CELL DYSCRASIA; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; RECURRENT DISEASE; REVIEW; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

GLOMERULONEPHRITIS; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROGNOSIS; RECURRENCE;

EID: 84884812070     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.07.004     Document Type: Review

References (173)

1. 2011 annual report. Organ Procurement and Transplantation Network (OPTN): 2013; (date accessed 04/04/2013):. http://optn.transplant.hrsa.gov/data/annualreport.asp.
2. Briganti E.M., Russ G.R., McNeil J.J., et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002, 347:103-109.
3. Halimi J.M., Laouad I., Buchler M., et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005, 5:2281-2288.
4. Amer H., Cosio F.G. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009, 20:2490-2492.
5. Knoll G.A. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management. Am J Kidney Dis 2009, 54:1131-1144.
6. Shamseddin M.K., Knoll G.A. Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol 2011, 6:1786-1793.
7. Amer H., Fidler M.E., Myslak M., et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007, 7:2748-2756.
8. Fernandez-Fresnedo G., Escallada R., Rodrigo E., et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002, 73:1345-1348.
9. Fellstrom B., Holdaas H., Jardine A.G., et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005, 79:205-212.
10. Opelz G., Zeier M., Laux G., et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006, 17:3257-3262.
11. Hiremath S., Fergusson D., Doucette S., et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007, 7:2350-2360.
12. Philipp T., Martinez F., Geiger H., et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010, 25:967-976.
13. Knoll G.A., Cantarovitch M., Cole E., et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation-study design. Nephrol Dial Transplant 2008, 23:354-358.
14. Ibrahim H.N., Jackson S., Connaire J., et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013, 24:320-327.
15. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
16. Sprangers B., Lefkowitz G.I., Cohen S.D., et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010, 5:790-797.
17. Dabade T.S., Grande J.P., Norby S.M., et al. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008, 8:1318-1322.
18. Cosyns J.P., Couchoud C., Pouteil-Noble C., et al. Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Clin Nephrol 1998, 50:144-153.
19. El-Zoghby Z.M., Grande J.P., Fraile M.G., et al. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009, 9:2800-2807.
20. Ponticelli C., Glassock R.J. De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease?. Transpl Int 2012, 25:1205-1210.
21. Poduval R.D., Josephson M.A., Javaid B. Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin Nephrol 2003, 23:392-399.
22. Truong L., Gelfand J., D'Agati V., et al. De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. Am J Kidney Dis 1989, 14:131-144.
23. Chan K.W., Chan G.S., Tang S. Glomerular pathology of allograft kidneys in Hong Kong. Transplant Proc 2005, 37:4293-4296.
24. Hofstra J.M., Beck L.H., Beck D.M., et al. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011, 6:1286-1291.
25. Beck L.H., Fervenza F.C., Beck D.M., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22:1543-1550.
26. Beck L.H., Salant D.J. Membranous nephropathy: recent travels and new roads ahead. Kidney Int 2010, 77:765-770.
27. Bruschi M., Carnevali M.L., Murtas C., et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 2011, 74:2008-2017.
28. Murtas C., Bruschi M., Candiano G., et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012, 7:1394-1400.
29. Prunotto M., Carnevali M.L., Candiano G., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010, 21:507-519.
30. Josephson M.A., Spargo B., Hollandsworth D., et al. The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review. Am J Kidney Dis 1994, 24:873-878.
31. Stahl R., Hoxha E., Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010, 363:496-498.
32. Debiec H., Martin L., Jouanneau C., et al. Autoantibodies specific for the phospholipase a2 receptor in recurrent and de novo membranous nephropathy. Am J Transplant 2011, 11:2144-2152.
33. Ruggenenti P., Cravedi P., Chianca A., et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012, 23:1416-1425.
34. Weber S., Gribouval O., Esquivel E.L., et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004, 66:571-579.
35. Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 2010, 25:25-31.
36. Hariharan S., Adams M.B., Brennan D.C., et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999, 68:635-641.
37. Hubsch H., Montane B., Abitbol C., et al. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol 2005, 20:210.
38. Newstead C.G. Recurrent disease in renal transplants. Nephrol Dial Transplant 2003, 18:vi68-vi74.
39. Fine R.N. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 2007, 22:496-502.
40. Ingulli E., Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children - a single-center experience. Transplantation 1991, 51:401-405.
41. Moroni G., Gallelli B., Quaglini S., et al. Long-term outcome of renal transplantation in adults with focal segmental glomerulosclerosis. Transpl Int 2010, 23:208-216.
42. Baum M.A. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 2004, 8:329-333.
43. Abbott K.C., Sawyers E.S., Oliver J.D., et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001, 37:366-373.
44. Canaud G., Dion D., Zuber J., et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2010, 25:1321-1328.
45. Wei C., Moller C.C., Altintas M.M., et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008, 14:55-63.
46. Maas R.J., Wetzels J.F., Deegens J.K. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 2012, 81:1043-1044.
47. Franco Palacios C.R., Lieske J.C., Wadei H.M., et al. Urine but Not serum soluble urokinase receptor (suPAR) May identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013, [epub ahead of print].
48. Freiberger V., Amann K., Heemann U., et al. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int 2009, 22:1110-1113.
49. Canaud G., Martinez F., Noel L.H., et al. Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. Transplant Rev (Orlando) 2010, 24:121-128.
50. Ingulli E., Tejani A., Butt K.M., et al. High-dose cyclosporine therapy in recurrent nephrotic syndrome following renal transplantation. Transplantation 1990, 49:219-221.
51. Salomon R., Gagnadoux M.F., Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003, 75:810-814.
52. Raafat R.H., Kalia A., Travis L.B., et al. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004, 44:50-56.
53. Canaud G., Zuber J., Sberro R., et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 2009, 9:1081-1086.
54. Faul C., Donnelly M., Merscher-Gomez S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14:931-938.
55. Cravedi P., Ruggenenti P., Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int 2010, 78:1068-1074.
56. Fornoni A., Sageshima J., Wei C., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011, 3:85ra46.
57. Joy M.S., Gipson D.S., Powell L., et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (novel therapies for resistant FSGS) study group. Am J Kidney Dis 2010, 55:50-60.
58. Trachtman H., Vento S., Gipson D., et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 2011, 12:8. 10.1186/1471-2369-12-8.
59. Gohh R.Y., Yango A.F., Morrissey P.E., et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005, 5:2907-2912.
60. Ohta T., Kawaguchi H., Hattori M., et al. Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 2001, 71:628-633.
61. Ponticelli C., Traversi L., Banfi G. Renal transplantation in patients with IgA mesangial glomerulonephritis. Pediatr Transplant 2004, 8:334-338.
62. Wyatt R.J., Julian B.A. IgA nephropathy. N Engl J Med 2013, 368:2402-2414.
63. Suzuki K., Honda K., Tanabe K., et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003, 63:2286-2294.
64. Ponticelli C., Traversi L., Feliciani A., et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001, 60:1948-1954.
65. Kim Y.S., Moon J.I., Jeong H.J., et al. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 2001, 71:233-238.
66. Andresdottir M.B., Haasnoot G.W., Doxiadis I.I., et al. Exclusive characteristics of graft survival and risk factors in recipients with immunoglobulin A nephropathy: a retrospective analysis of registry data. Transplantation 2005, 80:1012-1018.
67. Wang A.Y., Lai F.M., Yu A.W., et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 2001, 38:588-596.
68. McDonald S.P., Russ G.R. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 2006, 82:759-762.
69. Chailimpamontree W., Dmitrienko S., Li G., et al. Probability, predictors, and prognosis of posttransplantation glomerulonephritis. J Am Soc Nephrol 2009, 20:843-851.
70. Berthoux F., El D.S., Mariat C., et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 2008, 85:1505-1507.
71. Ortiz F., Gelpi R., Koskinen P., et al. IgA nephropathy recurs early in the graft when assessed by protocol biopsy. Nephrol Dial Transplant 2012, 27:2553-2558.
72. Andresdottir M.B., Haasnoot G.W., Persijn G.G., et al. HLA-B8, DR3: a new risk factor for graft failure after renal transplantation in patients with underlying immunoglobulin A nephropathy. Clin Transplant 2009, 23:660-665.
73. Mulay A.V., van W.C., Knoll G.A. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 2009, 9:804-811.
74. Oka K., Imai E., Moriyama T., et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 2000, 15:689-695.
75. Courtney A.E., McNamee P.T., Nelson W.E., et al. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?. Nephrol Dial Transplant 2006, 21:3550-3554.
76. Kennoki T., Ishida H., Yamaguchi Y., et al. Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation 2009, 88:935-941.
77. Meulders Q., Pirson Y., Cosyns J.P., et al. Course of Henoch-Schonlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation 1994, 58:1179-1186.
78. Martin S.J., Audrain M.A., Baranger T., et al. Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. Am J Kidney Dis 1997, 29:125-131.
79. Bachman U., Biava C., Amend W., et al. The clinical course of IgA-nephropathy and Henoch-Schonlein purpura following renal transplantation. Transplantation 1986, 42:511-515.
80. Moroni G., Gallelli B., Diana A., et al. Renal transplantation in adults with Henoch-Schonlein purpura: long-term outcome. Nephrol Dial Transplant 2008, 23:3010-3016.
81. Han S.S., Sun H.K., Lee J.P., et al. Outcome of renal allograft in patients with Henoch-Schonlein nephritis: single-center experience and systematic review. Transplantation 2010, 89:721-726.
82. Fervenza F.C., Sethi S., Glassock R.J. Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrol Dial Transplant 2012, 27:4288-4294.
83. Sethi S., Fervenza F.C. Membranoproliferative glomerulonephritis - a new look at an old entity. N Engl J Med 2012, 366:1119-1131.
84. Braun M.C., Stablein D.M., Hamiwka L.A., et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005, 16:2225-2233.
85. Little M.A., Dupont P., Campbell E., et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006, 69:504-511.
86. Lorenz E.C., Sethi S., Leung N., et al. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 2010, 77:721-728.
87. Lien Y.H., Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis 2000, 35:539-543.
88. Wu J., Jaar B.G., Briggs W.A., et al. High-dose mycophenolate mofetil in the treatment of posttransplant glomerular disease in the allograft: a case series. Nephron Clin Pract 2004, 98:c61-c66.
89. Smith R.J., Alexander J., Barlow P.N., et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007, 18:2447.
90. Zuber J., Le Q.M., Krid S., et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:3337-3354.
91. Krid S., Roumenina L.T., Beury D., et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012, 12:1938-1944.
92. Nester C., Stewart Z., Myers D., et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011, 6:1488-1494.
93. Leung N., Bridoux F., Hutchison C.A., et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012, 120:4292-4295.
94. Brunkhorst R., Kliem V., Koch K.M. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 1996, 72:465-467.
95. Andrejak M., Bariety J., Bedrossian J., et al. Cryoglobulinaemia in renal transplant recipients. Transplantation 1978, 26:446-447.
96. Basse G., Ribes D., Kamar N., et al. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia. Clin Nephrol 2006, 66:395-396.
97. Kamar N., Ribes D., Izopet J., et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006, 82:853-856.
98. Rostaing L., Weclawiak H., Izopet J., et al. Treatment of hepatitis C virus infection after kidney transplantation. Contrib Nephrol 2012, 176:87-96.
99. Baid-Agrawal S., Farris A.B., Pascual M., et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011, 80:879-885.
100. Noris M., Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010, 10:1517-1523.
101. Schmidt R.J., Venkat K.K., Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. Transplant Proc 1991, 23:3156-3157.
102. Pham P.T., Peng A., Wilkinson A.H., et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000, 36:844-850.
103. Crew R.J., Radhakrishnan J., Cohen D.J., et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 2005, 20:203-209.
104. Lam K., Martlew V., Walkinshaw S., et al. Successful management of recurrent pregnancy-related thrombotic thrombocytopaenia purpura in a renal transplant recipient. Nephrol Dial Transplant 2010, 25:2378-2380.
105. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
106. Bresin E., Daina E., Noris M., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1:88-99.
107. Noris M., Caprioli J., Bresin E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
108. Fremeaux-Bacchi V., Arzouk N., Ferlicot S., et al. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant 2007, 7:2047-2051.
109. Le Quintrec M., Zuber J., Moulin B., et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-675.
110. Donne R.L., Abbs I., Barany P., et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002, 40:E22.
111. Remuzzi G., Ruggenenti P., Codazzi D., et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002, 359:1671-1672.
112. Remuzzi G., Ruggenenti P., Colledan M., et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005, 5:1146-1150.
113. Saland J.M., Ruggenenti P., Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20:940-949.
114. Saland J.M., Shneider B.L., Bromberg J.S., et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009, 4:201-206.
115. Saland J.M., Emre S.H., Shneider B.L., et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006, 6:1948-1952.
116. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
117. Zuber J., Fakhouri F., Roumenina L.T., et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-657.
118. Le Quintrec M., Zuber J., Noel L.H., et al. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009, 9:1223-1229.
119. Dragon-Durey M.A., Sethi S.K., Bagga A., et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010, 21:2180-2187.
120. Kwon T., Dragon-Durey M.A., Macher M.A., et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008, 23:2088-2090.
121. Waters A.M., Pappworth I., Marchbank K., et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant 2010, 10:168-172.
122. Nyberg G., Akesson P., Norden G., et al. Systemic vasculitis in a kidney transplant population. Transplantation 1997, 63:1273-1277.
123. Goral S., Ynares C., Shappell S.B., et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003, 75:651-656.
124. Norby G.E., Strom E.H., Midtvedt K., et al. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study. Ann Rheum Dis 2010, 69:1484-1487.
125. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250.
126. Grimbert P., Frappier J., Bedrossian J., et al. Long-term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperatif de Transplantation d'ile de France. Transplantation 1998, 66:1000-1003.
127. Contreras G., Mattiazzi A., Guerra G., et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010, 21:1200-1207.
128. Burgos P.I., Perkins E.L., Pons-Estel G.J., et al. Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. Arthritis Rheum 2009, 60:2757-2766.
129. Moroni G., Tantardini F., Gallelli B., et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005, 45:903-911.
130. Moroni G., Torri A., Gallelli B., et al. The long-term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007, 7:2133-2139.
131. Moroni G., Ventura D., Riva P., et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004, 43:28-36.
132. Ponticelli C., Moroni G. Renal transplantation in lupus nephritis. Lupus 2005, 14:95-98.
133. Hill G.S., Nochy D. Antiphospholipid syndrome in systemic lupus erythematosus. J Am Soc Nephrol 2007, 18:2461-2464.
134. Prakash R., Miller C.C., Suki W.N. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995, 26:347-352.
135. Valeri A., Joseph R., Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 1999, 51:116-121.
136. Velik-Salchner C., Lederer W., Wiedermann F. Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation. Lupus 2011, 20:772.
137. Mondragon-Ramirez G., Bochicchio T., Garcia-Torres R., et al. Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS). Clin Transplant 1994, 8:93-96.
138. Canaud G., Bienaime F., Noel L.H., et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010, 10:2051-2060.
139. Gera M., Griffin M.D., Specks U., et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 2007, 71:1296-1301.
140. Nachman P.H., Segelmark M., Westman K., et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999, 56:1544-1550.
141. Rostaing L., Modesto A., Oksman F., et al. Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997, 29:96-102.
142. Lobbedez T., Comoz F., Renaudineau E., et al. Recurrence of ANCA-positive glomerulonephritis immediately after renal transplantation. Am J Kidney Dis 2003, 42:E2-E6.
143. Geetha D., Eirin A., True K., et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 2011, 91:1370-1375.
144. Wrenger E., Pirsch J.D., Cangro C.B., et al. Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transpl Int 1997, 10:152-156.
145. Little M.A., Hassan B., Jacques S., et al. Renal transplantation in systemic vasculitis: when is it safe?. Nephrol Dial Transplant 2009, 24:3219-3225.
146. Geetha D., Seo P., Specks U., et al. Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 2007, 7:2821-2825.
147. Deegens J.K., Artz M.A., Hoitsma A.J., et al. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease. Clin Nephrol 2003, 59:1-9.
148. Khandelwal M., McCormick B.B., Lajoie G., et al. Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 2004, 19:491-494.
149. Wang X.P., Fogo A.B., Colon S., et al. Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol 2005, 16:3563-3571.
150. Pedchenko V., Bondar O., Fogo A.B., et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010, 363:343-354.
151. Gillmore J.D., Lovat L.B., Persey M.R., et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001, 358:24-29.
152. Lachmann H.J., Goodman H.J., Gilbertson J.A., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371.
153. Dember L.M., Hawkins P.N., Hazenberg B.P., et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007, 356:2349-2360.
154. Pinney J.H., Lachmann H.J., Sattianayagam P.T., et al. Renal transplantation in systemic amyloidosis - importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013, 13:433-441.
155. Sattianayagam P.T., Gibbs S.D., Pinney J.H., et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010, 10:2124-2131.
156. Leung N., Griffin M.D., Dispenzieri A., et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005, 5:1660-1670.
157. Leung N., Lager D.J., Gertz M.A., et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004, 43:147-153.
158. Larsen T., Hammer A., Jorgensen K.A. Recurrence of light-chain deposition disease after renal transplantation. Scand J Urol Nephrol 2008, 42:187-188.
159. Kuypers D.R., Lerut E., Claes K., et al. Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. Transpl Int 2007, 20:381-385.
160. Kaposztas Z., Kahan B.D., Katz S.M., et al. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc 2009, 41:4407-4410.
161. Calls G.J., Torras A., Ricart M.J., et al. Fibrillary glomerulonephritis and pulmonary hemorrhage in a patient with renal transplantation. Clin Nephrol 1995, 43:180-183.
162. Samaniego M., Nadasdy G.M., Laszik Z., et al. Outcome of renal transplantation in fibrillary glomerulonephritis. Clin Nephrol 2001, 55:159-166.
163. Czarnecki P.G., Lager D.J., Leung N., et al. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 2009, 75:420-427.
164. Rosenstock J.L., Markowitz G.S., Valeri A.M., et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003, 63:1450-1461.
165. John G.T., Date A., Korula A., et al. Nondiabetic renal disease in noninsulin-dependent diabetics in a south Indian Hospital. Nephron 1994, 67:441-443.
166. Mou S., Wang Q., Liu J., et al. Prevalence of non-diabetic renal disease in patients with type 2 diabetes. Diabetes Res Clin Pract 2010, 87:354-359.
167. Soni S.S., Gowrishankar S., Kishan A.G., et al. Non diabetic renal disease in type 2 diabetes mellitus. Nephrology (Carlton) 2006, 11:533-537.
168. Yates C.J., Fourlanos S., Hjelmesaeth J., et al. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant 2012, 12:820-828.
169. Bloom R.D., Crutchlow M.F. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol 2008, 3:S38-S48.
170. Ishida-Oku M., Iwase M., Sugitani A., et al. A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor. Diabetologia 2010, 53:341-345.
171. Shaffer D., Simpson M.A., Madras P.N., et al. Kidney transplantation in diabetic patients using cyclosporine. Five-year follow-up. Arch Surg 1995, 130:283-287.
172. Boucek P., Saudek F., Pokorna E., et al. Kidney transplantation in type 2 diabetic patients: a comparison with matched non-diabetic subjects. Nephrol Dial Transplant 2002, 17:1678-1683.
173. Lufft V., Dannenberg B., Schlitt H.J., et al. Cardiovascular morbidity and mortality in patients with diabetes mellitus type I after kidney transplantation: a case-control study. Clin Nephrol 2004, 61:238-245.